healthandpharma2d
FDA Approves Ziihera as the First Dual HER2-Targeted Therapy for Biliary Tract Cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii), a novel therapy for ...
healthandpharma2d
How the ARANOTE Trial Results Could Advance Prostate Cancer Treatment
ONCOLife proudly presents an exclusive interview with Dr. Iris Kuss, VP and Global Development Lead Oncology at Bayer. In ...
healthandpharma4d
How Oncolytic Viruses Could Be a New Frontier in Transforming Cancer Treatment
Oncolytic viruses are a very promising class of therapeutic agents, with a broad range of types. In this exclusive interview ...
healthandpharma5d
Cambridge Researchers Launch Groundbreaking Study to Uncover Cancer Survival Secrets
Researchers from Cambridge University Hospitals, in collaboration with the NHS Health Research Authority, have launched the ...
healthandpharma16d
Overcoming Resistance in Cancer Treatment with Cytokine Therapies
Cytokine therapies have the potential to transform cancer treatment by enhancing the body’s immune response to fight cancer more effectively. In our interview with Caroline Loew, Ph.D., CEO of Mural ...
healthandpharma16d
FDA Approves MI Cancer Seek Test as a Groundbreaking Tool for Targeted Cancer Therapy
The FDA has approved Caris Life Sciences’ MI Cancer Seek, a pioneering diagnostic test combining Whole Exome and Whole ...
healthandpharma17d
IMUNON’s Novel Immunotherapy IMNN-001 Enhances Survival in Ovarian Cancer
IMUNON’s Phase 2 OVATION 2 study shows promising results for its immunotherapy, IMNN-001, in advanced ovarian cancer. Combined with standard chemotherapy, IMNN-001 improved overall survival by 35% and ...
healthandpharma19d
Novel Biomarker-Driven Treatments with ADCs in NSC Lung Cancer Management
Antibody-drug conjugates (ADCs) represent a significant breakthrough in oncology, offering targeted treatments, especially for lung cancer. In this insightful interview with Dr. Nicolas Girard, Head ...